HC Wainwright Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $3.00

Inovio Pharmaceuticals (NASDAQ:INO) had its target price cut by HC Wainwright from $5.00 to $3.00 in a research report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on INO. Oppenheimer dropped their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday. Finally, Royal Bank of Canada cut their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.40.

Inovio Pharmaceuticals Trading Down 4.0 %

Shares of NASDAQ:INO opened at $1.90 on Monday. The stock has a market capitalization of $49.59 million, a P/E ratio of -0.91 and a beta of 0.84. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75. The business has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $6.09.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 3,630 shares during the period. MetLife Investment Management LLC raised its holdings in Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals during the 2nd quarter worth approximately $82,000. American Century Companies Inc. raised its holdings in Inovio Pharmaceuticals by 62.2% during the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $71,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.